Bone Metastases

From ASCO 2013 – Updated Analysis of radium-223 dichloride (Ra-223) impact on skeletal-related events (SRE) from the phase III randomized trial (ALSYMPCA).

Ra-223 (Alpharadin)is an alpha-pharmaceutical targeting bone metastases (mets) with high-energy, short-range (< 100 ?m) alpha-particles. Currently it has been submitted to the FDA for approval, which we hope will happen by August 2013. In the phase 3, double-blind, randomized, multinational ALSYMPCA study, Ra-223 significantly improved overall survival (OS) in men with castrate resistant advanced prostate [...]

By Malecare|2017-10-19T10:50:08-04:00March 4th, 2013|Advanced Prostate Cancer, Alpharadin (radium-223), ASCO, Bone Metastases, Clinical Trials, Clinical Trials, Drugs & Treatments, Uncategorized, Understanding APC|0 Comments

More From the 2013 ASCO GU Conference – An Updated Analysis of the Phase III Randomized Trial (ALSYMPCA) of Radium-223 dichloride (Ra-223)

Ra-223 is an investigational alpha-pharmaceutical targeting bone metastases (mets) with high-energy, short-range alpha-particles. The recently completed phase 3, double-blind, randomized, multinational ALSYMPCA study showed that Ra-223 significantly improved over all survival (OS) in CRPC men with bone mets by a median increase of 3.6 months compared with placebo (median OS: 14.9 vs 11.3 mo; P [...]

By Malecare|2017-10-19T10:50:08-04:00February 28th, 2013|Advanced Prostate Cancer, Alpharadin (radium-223), ASCO, Bone Metastases, Clinical Trials, Clinical Trials, Drugs & Treatments, Uncategorized|0 Comments

Two New Sites Available for Early Access to Alpharadin

There are now two new, additional sites added to the Early Access Trial of the investigational treatment known as Radium-233 or Alpharadin for men with castrate resistant prostate cancer with multiple bone metastases. This post contains the most up to date and accurate information, the clinical trials.gov site is NOT currently accurate. Additionally, there are [...]

By Malecare|2017-10-19T10:50:24-04:00December 31st, 2012|Advanced Prostate Cancer, Alpharadin (radium-223), Bone Metastases, Clinical Trials, Clinical Trials, Drugs & Treatments, Metastases, Uncategorized|0 Comments

Dr. Sartor Announces Bayer has Requested FDA Approval of Alpharedin & He Will Join Malecare to Make a Pod Cast Upon its Approval

On Thursday evening I had the opportunity to meet Dr. Oliver Sartor from the University of Tulane. At that time he informed me that Bayer had finally submitted the required paperwork to the FDA for formal approval of radium-233 chloride. For those of you who are not familiar with Dr. Sartor, he is both an [...]

By Malecare|2012-12-17T09:18:40-05:00December 17th, 2012|Advanced Prostate Cancer, Alpharadin (radium-223), Bone Metastases, Clinical Trials, Clinical Trials, Drugs & Treatments, Early/Expanded Access Programs, FDA, On The Horizon, Radiotherapy, Uncategorized, Understanding APC|2 Comments

Two New Sites Open for Early/Expanded Access to Radium-233 (Alapharedin) in Fort Meyers, FL. & Philadelphia, PA

The Early/Expanded Access Committee has been continuing to work on getting additional sites open for men with advanced prostate cancer to get access to the yet unapproved drug Radium-233 Chloride (Alapharadin). Due to the hard work of this committee there are now sites in seven different states. In order to qualify for this treatment you [...]

By Malecare|2020-02-04T11:08:09-05:00December 7th, 2012|Advanced Prostate Cancer, Alpharadin (radium-223), Bone Metastases, Clinical Trials, Clinical Trials, Drugs & Treatments, Early/Expanded Access Programs, Uncategorized, Understanding APC|0 Comments

Another Site Added to the Early Access Program for Radium-223 Chloride (Alpharadin)

The Early Access Committee Announces an Additional Site for Radium-223 Chloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases We have been able to get Bayer to open another early access site for Alpharedin. This additional site is in Boston, Ma. In addition to this new site there are still three other sites. [...]

By Malecare|2020-02-04T11:08:05-05:00October 26th, 2012|Advanced Prostate Cancer, Alpharadin (radium-223), Bone Metastases, Clinical Trials, Clinical Trials, Drugs & Treatments, Early/Expanded Access Programs, Uncategorized, Understanding APC|2 Comments

The FDA Approves a New Non-Invasive, Non-Ionizing Radiation Therapy to Treat Pain from Bone Metastases

The big news from yesterday is that the Food and Drug Administration (FDA) has approved a MRI-guided, focused ultrasound therapy for the treatment of bone pain associated with metastatic advanced prostate cancer. In a media release written by InSight, an Israeli company states that its ExAblate® MRI-guided, focused ultrasound technology is indicated to treat pain [...]

By Malecare|2020-02-04T08:22:11-05:00October 24th, 2012|Advanced Prostate Cancer, Bone Metastases, Clinical Trials, Clinical Trials, Drugs & Treatments, Imaging, Metastases, Radiotherapy, Uncategorized, Understanding APC|1 Comment

New Site from the Early/Expanded Access Committee – Alpharedin Now available at Stanford University (plus 3 other sites)

There was just a new site opened for the early/expanded access program for Alpharedin (Radium-235). The new site is at Stanford University, California. This makes a total of four sites, but most of them have not been adequately supported by the drug company, Bayer. Hopefully, this site will be better supported, but if it too [...]

By Malecare|2017-10-19T10:50:43-04:00October 16th, 2012|Advanced Prostate Cancer, Alpharadin (radium-223), Bio Chemical Recurrence, Bone Metastases, Clinical Trials, Clinical Trials, Drugs & Treatments, Early/Expanded Access Programs, Uncategorized|0 Comments

Understanding Oligometastic Prostate Cancer & Our Ability to Successfully Treat It

It is the general consensus that prostate cancer when still confined to the prostate gland is gland curable, but when it has left the prostate gland and becoming metastatic it is no longer curable. But evidence now says there might be an intermediate stage where the cancer has spread outside the prostate gland but is [...]

By Malecare|2020-02-04T12:32:49-05:00October 15th, 2012|Advanced Prostate Cancer, Bio Chemical Recurrence, Bone Metastases, Drugs & Treatments, General Information, Metastases, oligometastic, Uncategorized, Understanding APC|4 Comments

A Common Advanced Prostate Cancer Emergency – Spinal Cord Compression

Spinal cord compression is not an uncommon occurrence in men with advanced prostate cancer. Bones are the most common target of advanced prostate cancer, including the spine. Sadly, there is often a delay in diagnosing spinal cord compression resulting from prostate cancer. These delays in diagnosis can influence the eventual functional outcome. Oncologists, primary care [...]

By Malecare|2017-10-19T10:50:45-04:00September 28th, 2012|Advanced Prostate Cancer, Bone Metastases, Drugs & Treatments, General Information, Hormone Therapy, How We Live, Research, Uncategorized, Understanding APC|0 Comments